Weekend reads: Women in science, creative peer review, is civil discourse about science still possible?
Another busy week at Retraction Watch. Here’s what was happening elsewhere:
Search Results for: lancet
Weekend reads: Fallout from STAP stem cell retractions, confessed HIV vaccine fraudster pleads not guilty
Another busy week at Retraction Watch, with developments in two closely watched cases at Nature and PNAS. Here’s what was happening around the web:
Braggadacio, information control, and fear: Life inside a Brigham stem cell lab under investigation
The following post was written by a former research fellow in the lab of Piero Anversa to whom we’ve promised confidentiality. Anversa has previously told us that he cannot comment because of an ongoing investigation. Regular readers of Retraction Watch will note the recent news regarding the work conducted in the laboratory of Piero Anversa … Continue reading Braggadacio, information control, and fear: Life inside a Brigham stem cell lab under investigation
NIH/Harvard team loses aging study to manipulated data
Age has retracted a 2012 article by a group of scientists from the National Institutes of Health and Brigham and Women’s Hospital in Boston after an NIH inquiry turned up evidence of data manipulation in the work. The article, “Aging decreases rate of docosahexaenoic acid synthesis-secretion from circulating unesterified α-linolenic acid by rat liver,” came … Continue reading NIH/Harvard team loses aging study to manipulated data
Harvard and the Brigham investigating leading heart group for “compromised” data
Circulation has retracted a 2012 study by a group of Harvard heart specialists over concerns of corrupt data, and the university is investigating. The group was led by Piero Anversa, a leading cardiologist, and Joseph Loscalzo — who will be familiar to readers of Circulation as the editor in chief of that journal. (Anversa’s also … Continue reading Harvard and the Brigham investigating leading heart group for “compromised” data
Novartis Diovan scandal claims two more papers
A complicated story involving Novartis’s valsartan (Diovan) has led to the retraction of two more papers, one cascading from the other. Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of … Continue reading Novartis Diovan scandal claims two more papers
Chronic fatigue syndrome researcher Mikovits, who championed link to XMRV, to publish book
Judy Mikovits, the chronic fatigue syndrome (CFS) researcher who had a paper linking the condition to XMRV retracted, has co-authored a book that’s coming out on May 6. In an announcement on Age of Autism, co-author Kent Heckenlively gives a taste of what readers might find in the book, titled PLAGUE – One Scientist’s Intrepid … Continue reading Chronic fatigue syndrome researcher Mikovits, who championed link to XMRV, to publish book
Weekend reads: A psychology researcher’s confession, a state senator’s plagiarism
Yet another busy week at Retraction Watch, with one of us taking part in a symposium on the future of science journalism for a few days. (See if you can find Ivan in this picture.) Here’s what was happening elsewhere on the web in science publishing and related issues:
Journal editor defends retraction of GMO-rats study while authors reveal some of paper’s history
The debate over the retraction of a highly controversial paper on the effects of GMOs on rats continues unabated. This week, Adriane Fugh-Berman and Thomas Sherman wrote on the Hastings Center website that
Weekend reads: Waste in research, a praise-worthy swift correction in NEJM, and more
The first full week of 2014 featured a slew of stories and commentary about scientific publishing and related issues. Here’s a sampling: